Literature DB >> 2424012

Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation.

H Sunada, B E Magun, J Mendelsohn, C L MacLeod.   

Abstract

The down-regulation and internalization of the epidermal growth factor (EGF) receptors induced by two separate anti-EGF monoclonal antibodies (mAbs), IgG1 mAb-225 and -455, and by EGF was examined. mAb-225 competitively inhibits EGF binding and it is internalized to an extent comparable to EGF. The antibody down-regulates surface EGF receptors in a dose-dependent manner. In contrast, mAb-455 does not competitively inhibit the binding of EGF or mAb-225, but it specifically immunoprecipitates the EGF receptor. mAb-455 also down-regulates the EGF receptor. Unlike EGF, which elicits phosphorylation of the receptor at tyrosine, threonine, and serine residues, neither of these antibodies elicits phosphorylation of the EGF receptor in intact A431 cells or in KB cells. Our studies suggest that EGF-stimulated phosphorylation of the receptor is not required for the internalization of the ligand-receptor complex.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2424012      PMCID: PMC323616          DOI: 10.1073/pnas.83.11.3825

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

Review 1.  Epidermal growth factor.

Authors:  G Carpenter; S Cohen
Journal:  Annu Rev Biochem       Date:  1979       Impact factor: 23.643

Review 2.  The phosphomannosyl recognition system for intracellular and intercellular transport of lysosomal enzymes.

Authors:  W S Sly; H D Fischer
Journal:  J Cell Biochem       Date:  1982       Impact factor: 4.429

3.  Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells.

Authors:  G N Gill; C S Lazar
Journal:  Nature       Date:  1981-09-24       Impact factor: 49.962

4.  A direct radioimmunoassay for human epidermal growth factor receptor using 32P-autophosphorylated receptor.

Authors:  H Sunada; C MacLeod; J Mendelsohn
Journal:  Anal Biochem       Date:  1985-09       Impact factor: 3.365

5.  Rapid enhancement of protein phosphorylation in A-431 cell membrane preparations by epidermal growth factor.

Authors:  G Carpenter; L King; S Cohen
Journal:  J Biol Chem       Date:  1979-06-10       Impact factor: 5.157

6.  Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431.

Authors:  H Haigler; J F Ash; S J Singer; S Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

7.  Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A431 human tumor cells.

Authors:  T Hunter; J A Cooper
Journal:  Cell       Date:  1981-06       Impact factor: 41.582

8.  Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes.

Authors:  H Ushiro; S Cohen
Journal:  J Biol Chem       Date:  1980-09-25       Impact factor: 5.157

9.  Rapid induction of morphological changes in human carcinoma cells A-431 by epidermal growth factors.

Authors:  M Chinkers; J A McKanna; S Cohen
Journal:  J Cell Biol       Date:  1979-10       Impact factor: 10.539

10.  Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture.

Authors:  D W Barnes
Journal:  J Cell Biol       Date:  1982-04       Impact factor: 10.539

View more
  74 in total

1.  Heparin-binding ligands mediate autocrine epidermal growth factor receptor activation In skin organ culture.

Authors:  S Stoll; W Garner; J Elder
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 2.  Monoclonal antibodies to epidermal growth factor receptors in studies of receptor structure and function.

Authors:  T Kawamoto; G H Sato; K Takahashi; M Nishi; S Taniguchi; J D Sato
Journal:  Cytotechnology       Date:  1990-05       Impact factor: 2.058

3.  Integrating anti-EGFR therapies in metastatic colorectal cancer.

Authors:  Sigurdis Haraldsdottir; Tanios Bekaii-Saab
Journal:  J Gastrointest Oncol       Date:  2013-09

4.  Immunocytochemical demonstration of the binding and internalization of growth hormone in GERL of Chang hepatoma cells.

Authors:  J J Wang; J P Chang; C S Teng
Journal:  Cell Tissue Res       Date:  1990-11       Impact factor: 5.249

Review 5.  Clinical experience with monoclonal antibodies to epidermal growth factor receptor.

Authors:  Emiliano Calvo; Eric K Rowinsky
Journal:  Curr Oncol Rep       Date:  2005-03       Impact factor: 5.075

6.  Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro.

Authors:  M Saki; M Toulany; W Sihver; M Zenker; J-M Heldt; B Mosch; H-J Pietzsch; M Baumann; J Steinbach; H P Rodemann
Journal:  Strahlenther Onkol       Date:  2012-08-10       Impact factor: 3.621

Review 7.  Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.

Authors:  Michael Campoli; Robert Ferris; Soldano Ferrone; Xinhui Wang
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

8.  Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor.

Authors:  Hong-Jun Liao; Graham Carpenter
Journal:  Cancer Res       Date:  2009-07-14       Impact factor: 12.701

9.  EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab.

Authors:  Chad A Reade; Apar Kishor Ganti
Journal:  Biologics       Date:  2009-07-13

10.  Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

Authors:  Doris R Siwak; Mark Carey; Bryan T Hennessy; Catherine T Nguyen; Mollianne J McGahren Murray; Laura Nolden; Gordon B Mills
Journal:  J Oncol       Date:  2009-11-19       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.